ShangBay Capital’s William Dai named to GrowthCap’s 2022 list of Top 25 Healthcare Investors

PALO ALTO, Calif.–(BUSINESS WIRE)–ShangBay Capital, a venture capital firm focused on investing in healthcare companies, is proud to announce that William Dai has been selected by GrowthCap for his contribution as one of the top investors in the health sector among an impressive list of winners.

The list recognizes exceptional and talented investors who help advance technologies and innovations to improve patient outcomes and save lives. Winners were selected based on their investment experience and track record, industry impact and advancement, and contributions to the growth and acceleration of portfolio companies.

William Dai, Founding Managing Partner, leads ShangBay’s healthcare investment business, focusing on medical technology investments. Since founding ShangBay Capital in 2015, William has led ShangBay to become a successful VC with 55 portfolio companies to date and multiple exits. William currently serves on the boards of the following companies including SetPoint Medical, Aqua Medical, Emboline, Meditrina, Corinth, FemDx, Apostle, Laplace Interventional, YorLabs, and previously served on the boards of NeuroVasc (acquired in 2019) and Arrinex (acquired by Stryker in 2019).

Previously, William’s professional experience spanned over 20 years in corporate finance, mergers and acquisitions and capital markets in Asia and the United States. Prior to founding ShangBay Capital, he was CFO of ShangPharma (NYSE: SHP), Nepstar Corporation (NYSE: NPD), Microport Scientific Corporation (HK: 00853) and Boston Scientific China. In these roles, William was responsible for the overall execution of business transactions to ensure the success of the business.

“ShangBay Capital is committed to supporting entrepreneurs who create solutions for today’s unmet clinical needs. During the pandemic, we have seen a huge need for disruptive healthcare solutions for people around the world. At ShangBay Capital, it is extremely rewarding to support and partner with world-class founders who are creating breakthrough medical technologies that help improve patient outcomes and save lives,” said William Dai.

Comments are closed.